-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
-
2023-504226-18-00
5
2022-11-30
NMDAR or LGI1 mediated autoimmune Encephalitis
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-513185-19-00
9
2022-07-13
Extensive stage small cell lung cancer (ES-SCLC)
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-523151-66-00
6
2026-03-14
Haemorrhagic shock
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519404-27-00
5
2026-01-16
IDH-mutant grade 2 or 3 astrocytoma
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-519829-38-00
5
2026-01-09
Heart failure due to systemic left ventricular systolic dysfunction
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2024-520086-31-00
6
2026-01-07
Hypertrophic cardiomyopathy
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration